jRCT2031240473招募中不适用
33-505 : Special Drug Use-Results Survey of OPDIVO (Pediatric Patients with Recurrent or Refractory Classical Hodgkin Lymphoma)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 20
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- No limit 至 15age old not（—）
- 性别
- All
入选标准
- •Pediatric patients with recurrent or refractory classical hodgkin lymphoma, who have recieved OPDIVO for the first time
排除标准
- •'Patients who have received OPDIVO previously
结局指标
主要结局
-
'[Safety] a) Occurrence status of adverse drug reactions and infections b) Adverse events
次要结局
未报告次要终点
研究者
相似试验
已完成
Unknown
Special Drug Use-Results Survey of OPDIVO (classical Hodgkin's lymphoma)classical Hodgkin's lymphomaJPRN-jRCT1080224013ONO PHARMACEUTICAL CO.,LTD.250
已完成
Unknown
Special Drug Use-Results Survey of OPDIVO (NSCLC)non-small cell lung cancerJPRN-jRCT1080223216ONO PHARMACEUTICAL CO., LTD.1,000
已完成
Unknown
Special Drug Use-Results Survey of OPDIVO (RCC)Renal Cell CancerJPRN-jRCT1080224010ONO PHARMACEUTICAL CO.,LTD.500
已完成
Unknown
33-104 : Drug Use-Results Survey of OPDIVOnresectable advanced/recurrent malignant pleural mesothelioma that has progressed after cancer chemJPRN-jRCT2011230029Kuro Toshihiko100
Unknown
Unknown
Drug Use-Results Survey of OPDIVO (malignant melanoma)Malignant melanomaJPRN-jRCT1080223217ONO PHARMACEUTICAL CO., LTD.1,700